The company holds investments in unlisted shares which are not publicly traded. These investments are initially recognised at transaction price and subsequently measured at cost less any accumulated impairment losses, on the basis that fair value cannot be reliably measured without undue cost or effort.
At each reporting date, the directors assess whether there is objective evidence of impairment. If such evidence exists, the investment is written down to its estimated recoverable amount, with the impairment loss recognised immediately in profit or loss. Impairment losses are not subsequently reversed.